Comparative Effectiveness of Ultrasound-Guided Intratendinous Prolotherapy Injection with Conventional Treatment to Treat Focal Supraspinatus Tendinosis

Figure 3

Echogenicity measurement of tendinosis (a) and normal tendon (b) at baseline, which was 5.56 dB and 19.50 dB, respectively, giving a ratio of 0.26. Echogenicity measurement of tendinosis (c) and normal tendon (d) at 12 weeks after injection, which was 20.07 dB and 28.97 dB, respectively, giving a ratio of 0.70, which showed an increase in ratio. Transverse sonographic image of the supraspinatus tendon at baseline (a, b) and at 12 weeks (c, d) at the same section showing almost similar humeral head diameter. The tendinosis measured with continuous trace (b) on cross section is almost not visible at 12 weeks (d) marked with .